[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1047284A1 - 2-amino-benzoxazinone derivatives for the treatment of obesity - Google Patents

2-amino-benzoxazinone derivatives for the treatment of obesity

Info

Publication number
HK1047284A1
HK1047284A1 HK02109007.0A HK02109007A HK1047284A1 HK 1047284 A1 HK1047284 A1 HK 1047284A1 HK 02109007 A HK02109007 A HK 02109007A HK 1047284 A1 HK1047284 A1 HK 1047284A1
Authority
HK
Hong Kong
Prior art keywords
obesity
amino
treatment
benzoxazinone derivatives
benzoxazinone
Prior art date
Application number
HK02109007.0A
Other languages
English (en)
Inventor
Harold Francis Hodson
Robert Downham
Timothy John Mitchell
Beverley Jane Carr
Christopher Robert Dunk
Michael John Palmer Richard
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Publication of HK1047284A1 publication Critical patent/HK1047284A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HK02109007.0A 1999-01-08 2002-12-12 2-amino-benzoxazinone derivatives for the treatment of obesity HK1047284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9900416.0A GB9900416D0 (en) 1999-01-08 1999-01-08 Inhibitors
PCT/GB2000/000031 WO2000040569A1 (en) 1999-01-08 2000-01-06 2-amino-benzoxazinone derivatives for the treatment of obesity

Publications (1)

Publication Number Publication Date
HK1047284A1 true HK1047284A1 (en) 2003-02-14

Family

ID=10845777

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02109007.0A HK1047284A1 (en) 1999-01-08 2002-12-12 2-amino-benzoxazinone derivatives for the treatment of obesity

Country Status (22)

Country Link
US (2) US6656934B2 (ru)
EP (1) EP1144395B1 (ru)
JP (1) JP2002534419A (ru)
KR (1) KR100615914B1 (ru)
CN (1) CN100480245C (ru)
AR (1) AR022203A1 (ru)
AT (1) ATE293610T1 (ru)
AU (1) AU770342B2 (ru)
CA (1) CA2359987C (ru)
DE (1) DE60019556T2 (ru)
DK (1) DK1144395T3 (ru)
ES (1) ES2240051T3 (ru)
GB (1) GB9900416D0 (ru)
HK (1) HK1047284A1 (ru)
HU (1) HUP0104909A3 (ru)
MY (1) MY129247A (ru)
NO (1) NO321058B1 (ru)
NZ (1) NZ512739A (ru)
PL (1) PL350412A1 (ru)
PT (1) PT1144395E (ru)
RU (1) RU2244711C2 (ru)
WO (1) WO2000040569A1 (ru)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900416D0 (en) * 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
CA2286451A1 (en) * 1999-10-14 2001-04-14 Grant A. Mitchell Hormone-sensitive lipase mediated male infertility
GB0001572D0 (en) 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
BRPI0112014B1 (pt) 2000-06-27 2016-09-13 Hoffmann La Roche processo para a preparação de uma composição farmacêutica na forma de estruturas semelhantes à esponja ou espuma e porosas, e, composição farmacêutica
PL204443B1 (pl) 2000-07-28 2010-01-29 Hoffmann La Roche Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe
AU8969601A (en) 2000-07-28 2002-02-13 Hoffmann La Roche New use of lipase inhibitors
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
US6943001B2 (en) 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
EP1578987A2 (en) 2001-08-03 2005-09-28 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
CA2457976A1 (en) 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
PL368994A1 (en) * 2001-08-30 2005-04-04 Alizyme Therapeutics Limited Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
ES2278077T3 (es) 2001-08-31 2007-08-01 Sanofi-Aventis Deutschland Gmbh Derivados de diarilcicloalquilo, procedimiento para su preparacion y su uso como activadores de ppar.
US7064122B2 (en) 2001-12-20 2006-06-20 Osi Pharmaceuticals, Inc. Pancreatic lipase inhibitor compounds, their synthesis and use
US7223796B2 (en) 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7078404B2 (en) 2002-04-11 2006-07-18 Sanofi-Aventis Deutschland Gmbh Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7262220B2 (en) 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
NZ537603A (en) 2002-07-12 2006-09-29 Sanofi Aventis Deutschland Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US20040157922A1 (en) 2002-10-04 2004-08-12 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en) 2002-10-12 2007-04-24 Sanofi-Aventis Deutschland Gmbh Bicyclic inhibitors of hormone sensitive lipase
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US20040242583A1 (en) 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7196114B2 (en) 2003-02-17 2007-03-27 Sanofi-Aventis Deutschland Gmbh Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2004110338A2 (en) * 2003-06-12 2004-12-23 Biomas Ltd. Methods of treating obesity and related disorders using tellurium and selenium compounds
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1807063A2 (en) 2004-10-25 2007-07-18 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
DE102004059470A1 (de) * 2004-12-10 2006-06-14 Lanxess Deutschland Gmbh Verfahren zur Herstellung von Carbaminsäureester-Derivaten
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US7737146B2 (en) 2005-10-25 2010-06-15 Council Of Scientific And Industrial Research Compound, useful for pancreatic lipase inhibition and the process for isolation thereof
JP5424480B2 (ja) 2006-03-13 2014-02-26 杏林製薬株式会社 Ｇｓｋ−３インヒビターとしてのアミノキノロン
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EA200900392A1 (ru) 2006-09-07 2010-06-30 Никомед Гмбх Комбинированное лечение сахарного диабета
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
EP2152663B1 (en) 2007-06-04 2014-03-19 Ben Gurion University of the Negev Research and Development Authority Tri-aryl compounds and compositions comprising the same
KR101563018B1 (ko) 2007-09-11 2015-10-23 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP2010254623A (ja) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2482823A2 (en) 2009-10-02 2012-08-08 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
JP5715710B2 (ja) * 2011-01-13 2015-05-13 ノバルティス アーゲー 新規複素環誘導体および神経障害の処置におけるそれらの使用
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
CN104374836A (zh) * 2014-09-19 2015-02-25 安徽安科生物工程（集团）股份有限公司 西替利司他及有关杂质的hplc测定方法
CN105622539B (zh) * 2016-03-11 2016-11-23 中山万汉医药科技有限公司 一种西替利司他的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450700A (en) * 1966-12-20 1969-06-17 Upjohn Co 2-tertiary amino-4h-3,1-benzoxazin-4-ones
DE2315303A1 (de) * 1973-03-27 1974-10-17 Bayer Ag Verfahren zur herstellung von n-substituierten 2-amino-3,1-benzoxazin-4-onen
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
NZ210669A (en) * 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
US4665070A (en) 1985-06-25 1987-05-12 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use
US4745116A (en) 1985-06-25 1988-05-17 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use
US5652237A (en) * 1994-09-09 1997-07-29 Warner-Lambert Company 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
GB9900416D0 (en) * 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors

Also Published As

Publication number Publication date
ATE293610T1 (de) 2005-05-15
HUP0104909A2 (hu) 2002-04-29
NO20013380L (no) 2001-09-07
US20030191123A1 (en) 2003-10-09
CA2359987A1 (en) 2000-07-13
NO321058B1 (no) 2006-03-06
KR20010108073A (ko) 2001-12-07
CA2359987C (en) 2008-03-25
DE60019556D1 (de) 2005-05-25
AU770342B2 (en) 2004-02-19
MY129247A (en) 2007-03-30
DE60019556T2 (de) 2006-02-23
AU1884500A (en) 2000-07-24
US6656934B2 (en) 2003-12-02
WO2000040569A9 (en) 2002-02-28
WO2000040569A8 (en) 2001-03-15
NO20013380D0 (no) 2001-07-06
RU2244711C2 (ru) 2005-01-20
DK1144395T3 (da) 2005-08-15
EP1144395B1 (en) 2005-04-20
PL350412A1 (en) 2002-12-02
PT1144395E (pt) 2005-08-31
HUP0104909A3 (en) 2004-11-29
WO2000040569A1 (en) 2000-07-13
US20030013707A1 (en) 2003-01-16
JP2002534419A (ja) 2002-10-15
KR100615914B1 (ko) 2006-08-28
GB9900416D0 (en) 1999-02-24
US7776853B2 (en) 2010-08-17
ES2240051T3 (es) 2005-10-16
AR022203A1 (es) 2002-09-04
CN100480245C (zh) 2009-04-22
EP1144395A1 (en) 2001-10-17
NZ512739A (en) 2003-10-31
CN1354747A (zh) 2002-06-19

Similar Documents

Publication Publication Date Title
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
AU2935200A (en) Compounds for the treatment of obesity
HK1047588A1 (en) 2-Amino-4H-3,1-benzoxazine-4-one derivatives for the treatment of obesity
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
HK1048073A1 (en) Use of xenon for treating neurointoxications.
HUP0105036A3 (en) Imidazo-quinolin derivatives for treating sexual disturbances
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL136960A0 (en) Combination therapy for the treatment of migraine
GB9925136D0 (en) Novel treatment
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL144186A0 (en) Novel treatment
AU7750100A (en) Method for the treatment of obesity
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
HU0001891D0 (en) Medicament for the treatment of migraine
IL136962A0 (en) Combination therapy for the treatment of migraine
IL136024A0 (en) Combination therapy for the treatment of migraine
AU2000272704A1 (en) Use of compounds for the treatment of obesity
GB9924275D0 (en) Method for the treatment of obesity
GB9926206D0 (en) Anti-snoring treatment
NZ514013A (en) Treatment of hiatial hernia
SI1147083T1 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
GB9910545D0 (en) The treatment of acarids
SI1068184T1 (en) N-aryloxyethylamine derivatives for the treatment of depression

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130106